Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
3 Pharma Stocks' Post-Earnings Price Moves
06:06am, Thursday, 04'th Aug 2022
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Why AbbVie Is A Top 25 Dividend Giant
08:01am, Tuesday, 02'nd Aug 2022
AbbVie has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a stunning $30.38B worth of stock held by ETFs, and above-average ''DividendRank'' statistics including a strong 4.02% yield
Merck And AbbVie Q2: Pipeline And Dividends In Focus
08:38am, Monday, 01'st Aug 2022
Both Merck and AbbVie reported their Q2 earnings last week, and this article provides a review of their earnings. We like both given their strong pipeline and safe dividends.
3 Dividend Aristocrats to Buy in August
05:57am, Sunday, 31'st Jul 2022
These stocks have reliable dividends and strong underlying businesses.
Earn $300 in Quarterly Retirement Dividends With 3 Easy Steps
11:00am, Saturday, 30'th Jul 2022
With the market down close to 20% this year, passive income has become more important.
3 Stocks We Think Could Beat the Market in the Second Half of 2022
06:08am, Saturday, 30'th Jul 2022
These stocks share several things in common.
Why AbbVie Stock Is Tanking Today
06:21pm, Friday, 29'th Jul 2022
The drugmaker's Q2 results aren't sitting well with shareholders today.
AbbVie's (ABBV) Q2 Earnings Beat Estimates, Revenues Lag
05:07pm, Friday, 29'th Jul 2022
AbbVie's earnings (ABBV) beat estimates for second-quarter 2022, while sales miss the same. ABBV's immunology and neuroscience drugs drive sales.
AbbVie Inc. (ABBV) CEO Rick Gonzalez on Q2 2022 Results - Earnings Call Transcript
03:36pm, Friday, 29'th Jul 2022
AbbVie Inc. (NYSE:ABBV ) Q2 2022 Results Conference Call July 29, 2022 9:00 AM ET Company Participants Liz Shea - Head, IR Rick Gonzalez - Chairman and CEO Rob Michael - Vice Chairman and President Je
ABBV Stock Slips as AbbVie Faces Opioid Lawsuits
11:39am, Friday, 29'th Jul 2022
AbbVie (NYSE: ABBV ) recently published the company's second-quarter 2022 financial data. The results weren't very different from what Wall Street's analysts had expected.
AbbVie Ekes Out Narrow Second-Quarter Beat, Confirms 2022 Outlook
08:57am, Friday, 29'th Jul 2022
AbbVie narrowly topped second-quarter expectations Friday and reaffirmed its earnings outlook. But AbbVie stock fell early.
AbbVie reports an increase in second-quarter revenue, led by sales of Humira
08:17am, Friday, 29'th Jul 2022
Shares of AbbVie Inc. ABBV, -0.93% were down 1.3% in premarket trading on Friday though the company met earnings and revenue expectations for the second quarter of the year. AbbVie had earnings of $92
Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August
02:20pm, Thursday, 28'th Jul 2022
Are These Good Long Term Investments Into Cannabis? The post Best Cannabis Stocks To Buy Long Term? 2 To Watch Before August appeared first on Marijuana Stocks | Cannabis Investments and News. Roots o
Should You Buy AbbVie Ahead Of Earnings?
08:41am, Thursday, 28'th Jul 2022
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
AbbVie Q2 Preview: Can Shares Retain Their Strength?
06:34pm, Wednesday, 27'th Jul 2022
There has been a surplus of buyers for AbbVie shares in 2022, with shares gaining a double-digit 15% and outperforming its Zacks Industry by a fair margin.
